Optimization of a multiplex CRISPR/Cas system for use as an antiviral therapeutic.

Published

Journal Article

RNA-guided endonucleases or CRISPR/Cas systems have been widely employed for gene engineering/DNA editing applications, and have recently been used against a variety of dsDNA viruses as a potential therapeutic. However, in vivo delivery to specific tissue reservoirs using adeno-associated virus (AAV) vectors is problematic due to the large coding requirement for the principal effector commonly used in these applications, Streptococcus pyogenes (Spy) Cas9. Here we describe design of a minimal CRISPR/Cas system that is capable of multiplexing and can be packaged into a single AAV vector. This system consists of the small Type II Cas9 protein from Staphylococcus aureus (Sau) driven by a truncated CMV promoter/enhancer, and flanked 3' by a poly(A) addition signal, as well as two sgRNA expression cassettes driven by either U6 or ∼70-bp tRNA-derived Pol III promoters. Specific protocols for construction of these AAV vector scaffolds, shuttle cloning of their contents into AAV and lentiviral backbones, and a quantitative luciferase assay capable of screening for optimal sgRNAs, are detailed. These protocols can facilitate construction of AAV vectors that have optimal multiplexed sgRNA expression and function. These will have potential utility in multiplex applications, including in antiviral therapy in tissues chronically infected with a pathogenic DNA virus.

Full Text

Duke Authors

Cited Authors

  • Kennedy, EM; Kornepati, AVR; Mefferd, AL; Marshall, JB; Tsai, K; Bogerd, HP; Cullen, BR

Published Date

  • December 2015

Published In

Volume / Issue

  • 91 /

Start / End Page

  • 82 - 86

PubMed ID

  • 26291065

Pubmed Central ID

  • 26291065

Electronic International Standard Serial Number (EISSN)

  • 1095-9130

Digital Object Identifier (DOI)

  • 10.1016/j.ymeth.2015.08.012

Language

  • eng

Conference Location

  • United States